share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K：重大事件
美股SEC公告 ·  10/04 20:04

Moomoo AI 已提取核心信息

Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, announced the appointment of Dr. Jeremy R. Graff as President and Chief Development Officer effective September 30, 2024. Dr. Graff, with over 25 years of experience in the biotech and pharmaceutical industry, has held various C-level and senior executive positions and has a strong background in the development of targeted cancer therapies. Prior to joining Allarity, he served as a consultant to the company and held roles at IMV, Inc., HiberCell, and Biothera Pharmaceuticals, Inc. He also worked at Eli Lilly for nearly 17 years. Dr. Graff's appointment is part of a strategic move to strengthen the company's leadership as it advances its clinical development programs, particularly the stenoparib PARP inhibitor program. Alongside Dr. Graff's appointment, Allarity has also brought on Dr. Jose Iglesias as Consultant Chief Medical Officer and Jesper Høiland as Strategic Advisor. The company is focused on the development of stenoparib using its Drug Response Predictor (DRP®) companion diagnostic for patient selection in ongoing clinical trials.
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, announced the appointment of Dr. Jeremy R. Graff as President and Chief Development Officer effective September 30, 2024. Dr. Graff, with over 25 years of experience in the biotech and pharmaceutical industry, has held various C-level and senior executive positions and has a strong background in the development of targeted cancer therapies. Prior to joining Allarity, he served as a consultant to the company and held roles at IMV, Inc., HiberCell, and Biothera Pharmaceuticals, Inc. He also worked at Eli Lilly for nearly 17 years. Dr. Graff's appointment is part of a strategic move to strengthen the company's leadership as it advances its clinical development programs, particularly the stenoparib PARP inhibitor program. Alongside Dr. Graff's appointment, Allarity has also brought on Dr. Jose Iglesias as Consultant Chief Medical Officer and Jesper Høiland as Strategic Advisor. The company is focused on the development of stenoparib using its Drug Response Predictor (DRP®) companion diagnostic for patient selection in ongoing clinical trials.
Allarity Therapeutics，Inc.（纳斯达克：ALLR）是一家临床阶段的生物制药公司，宣布任命Jeremy R. Graff博士为总裁兼首席发展官，任职日期为2024年9月30日。Graff博士在生物科技和药品行业拥有超过25年的经验，曾担任过各种C级别和高级执行官职务，并在靶向癌症治疗的开发方面具有丰富背景。在加入Allarity之前，他曾担任该公司顾问，并在IMV，Inc.，HiberCell和Biothera Pharmaceuticals，Inc.担任职位。他还曾在Eli Lilly工作了近17年。Graff博士的任命是公司加强领导层的战略举措之一，以推进其临床开发项...展开全部
Allarity Therapeutics，Inc.（纳斯达克：ALLR）是一家临床阶段的生物制药公司，宣布任命Jeremy R. Graff博士为总裁兼首席发展官，任职日期为2024年9月30日。Graff博士在生物科技和药品行业拥有超过25年的经验，曾担任过各种C级别和高级执行官职务，并在靶向癌症治疗的开发方面具有丰富背景。在加入Allarity之前，他曾担任该公司顾问，并在IMV，Inc.，HiberCell和Biothera Pharmaceuticals，Inc.担任职位。他还曾在Eli Lilly工作了近17年。Graff博士的任命是公司加强领导层的战略举措之一，以推进其临床开发项目，尤其是stenoparib PARP抑制剂计划。除了任命Graff博士外，Allarity还聘请Jose Iglesias博士担任首席医疗官顾问，Jesper Høiland担任战略顾问。该公司专注于利用其Drug Response Predictor（DRP®）伴随诊断，开发stenoparib用于正在进行的临床试验中的患者选择。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间